We develop targeted therapeutics to enhance the body’s natural immune response, reducing inflammation and restoring immune balance.
By selectively isolating a key portion of a natural SERPIN protein, our targeted therapeutic, known as SP16, restores balance to harmful inflammatory environments, creating an entirely new class of therapeutics for unmet medical needs.
Targeted
SP16 uses a selective and precise mechanism to restore inflammatory equilibrium, with no known adverse effects.
Potent
In AMI, a single SP16 injection preserved heart function, reduced infarcts, and decreased biomarkers of cardiac injury.
Balancing
SP16 targets a receptor
that restores
homeostatic balance to cells experiencing inflammation.
Serpin Pharma’s patent estate includes 14 patent applications
13 patents out of 14 patent applications have been approved
- IP covers Composition of Matter as well as the Use of SERPIN Peptide Drug and Analogs
- SP16 is a fragment of a natural molecule (currently a plasma derived generic drug) with a modification to the sequence that yielded an enhanced affinity to the LRP1 receptor (expiration 2041)
- SP16 analogs are shorter peptide drugs molded on SP16 with extensive modifications outside of the binding motif
Global Anti-Inflammatory Therapeutics Market to Reach $130.9 Billion by 20261
“One of the most important medical discoveries of the past two decades has been the realization that the immune system and inflammatory processes are involved in not just a few select disorders, but a wide variety of mental and physical health problems that dominate present-day morbidity and mortality worldwide.”2
References
¹Global data. Retrieved from https://www.globaldata.com.
²Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., Franceschi, C., … & Slavich, G. M. (2019). Chronic inflammation in the etiology of disease across the life span. Nature medicine, 25(12), 1822-1832.
